Evoke Pharma, Inc. Announces Reverse Stock Split

Core Points - Evoke Pharma, Inc. has announced a 1-for-12 reverse stock split of its common stock, effective August 1, 2024, to comply with Nasdaq's minimum bid price requirement [1][3] - The reverse stock split was approved by stockholders at the 2024 annual meeting, allowing the Board to implement a split ratio between 1-for-2 and 1-for-20 [2] - Following the reverse stock split, every 12 shares will convert into one share, with no change in par value or authorized shares, and fractional shares will be compensated with cash [2][4] Company Overview - Evoke Pharma is a specialty pharmaceutical company focused on developing treatments for gastrointestinal diseases, particularly GIMOTI® (metoclopramide) nasal spray for diabetic gastroparesis [6][7] - Diabetic gastroparesis is a significant GI disorder affecting millions, characterized by delayed gastric emptying, which can complicate medication absorption [7]